ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

9776	Companies
195668	Keywords
126689	Articles
104037	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 09/26/2025 at 07:05, 4 months 4 days ago

Strategic Partnership for Innovation in Immunotherapy

Strategic Partnership Oncology Industrial Support Immunotherapy Innovation Collaborative Research
PRESS RELEASE

published on 09/26/2025 at 07:00, 4 months 4 days ago

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
OSE Immunotherapeutics, Inserm Transfert, and Nantes University form a strategic partnership to advance immunotherapy for oncology, inflammation, and autoimmunity. The collaboration combines academic research and industrial expertise

Innovation Partnership Oncology Collaboration Immunotherapy
BRIEF

published on 09/24/2025 at 08:05, 4 months 6 days ago

OSE Immunotherapeutics Corrects Voting Rights Error Before General Meeting

Voting Rights Shareholder Meeting Accusations Material Error Proxy Firms
PRESS RELEASE

published on 09/24/2025 at 08:00, 4 months 6 days ago

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
OSE Immunotherapeutics corrects material error in total number of shares and voting rights, refutes accusations, and provides clarity on shareholder agreements and proxy advisory recommendations

Correction Proxy Advisory Shareholder Agreements OSE Immunotherapeutics Material Error
BRIEF

published on 09/23/2025 at 22:35, 4 months 6 days ago

OSE Immunotherapeutics Responds to Court Decision

General Meeting Shareholder Rights OSE Immunotherapeutics Nantes Commercial Court Voting Rights Error
PRESS RELEASE

published on 09/23/2025 at 22:30, 4 months 6 days ago

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court regarding a shareholder action and prepares for the General Meeting on September 30, 2025, ensuring transparency and commitment

Transparency General Meeting OSE Immunotherapeutics Shareholder Action Nantes Commercial Court
BRIEF

published on 08/29/2025 at 08:05, 5 months 1 day ago

OSE Immunotherapeutics Clarifies Strategy Amid Shareholder Activism

Strategic Priorities Legal Proceedings OSE Immunotherapeutics Shareholder Activism Tedopi® And Lusvertikimab
PRESS RELEASE

published on 08/29/2025 at 08:00, 5 months 1 day ago

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
OSE Immunotherapeutics reaffirms strategic priorities with comprehensive Q&A document ahead of AGM. Company focuses on Tedopi® and Lusvertikimab programs for value creation

Strategic Priorities OSE Immunotherapeutics Lusvertikimab Shareholder Q&A Tedopi®
BRIEF

published on 08/25/2025 at 07:05, 5 months 5 days ago

OSE Immunotherapeutics: New Governance and Strategic Objectives

Shareholders Biotechnology Governance Strategy Tedopi And Lusvertikimab
PRESS RELEASE

published on 08/25/2025 at 07:00, 5 months 5 days ago

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
OSE Immunotherapeutics announces proposed governance evolution and reaffirms strategic priorities ahead of Annual General Meeting. Company focuses on Tedopi® and Lusvertikimab to unlock full potential

Strategic Priorities Governance Evolution OSE Immunotherapeutics Lusvertikimab Tedopi

Accesswire

Published on 01/30/2026 at 14:00, 4 hours 20 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 9 hours 45 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 10 hours 20 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 16 hours 5 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 18 hours 20 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 18:17, 2 minutes ago

POS-Transaction in Own Shares
Published on 01/30/2026 at 18:17, 2 minutes ago

Holding(s) in Company
Published on 01/30/2026 at 17:55, 25 minutes ago

Wellington College International to Open First African School in Alaro City, Lagos in 2027
Published on 01/30/2026 at 17:29, 51 minutes ago

EQS-Adhoc: The Payments Group Holding GmbH & Co. KGaA: The Payments Group Holding – Successful issuance of convertible bond
Published on 01/30/2026 at 17:09, 1 hour 11 minutes ago

Halfords Group PLC: Total Voting Rights

Les Echos

Published on 01/30/2026 at 17:45, 35 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 10 hours 20 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE